Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2016-04-22 | Mr. Neff received a B.A. from Claremont McKenna College with concentrations in Molecular Biology and Government. He studied Economics and Finance at the University of Chicago Graduate School of Business. |
| 2017-04-24 | Mr. Neff received a B.A. from Claremont McKenna College with concentrations in Molecular Biology and Government. Subsequently he studied Economics and Finance at the University of Chicago Graduate School of Business. |
| 2018-04-24 | Mr. Neff received a Bachelor of Arts degree from Claremont McKenna College with concentrations in Molecular Biology and Government. Subsequently he studied economics and finance at the University of Chicago Graduate School of Business, and was a Fellow of the Thomas J. Watson Foundation. He was employed as an investment banker first at PaineWebber Incorporated (1983-1988) and then at Lazard Freres & Co. through 1992. |
| 2019-04-23 | Mr. Neff received a Bachelor of Arts degree from Claremont McKenna College with concentrations in Molecular Biology and Government. Subsequently he studied economics and finance at the University of Chicago Graduate School of Business, and was a Fellow of the Thomas J. Watson Foundation. He was employed as an investment banker first at PaineWebber Incorporated (1983-1988) and then at Lazard Freres & Co. through 1992. Mr. Neff was founder of Pharmaceutical Partners I and Pharmaceutical Partners II, the pioneer entities investing in drug royalties and predecessors to what is now named Royalty Pharma. He left the group in 1998 to concentrate on FibroGen but remained as Managing General Partner of Pharmaceutical Partners I and Pharmaceutical Partners II until all assets were distributed to partners through 2009. He was also founder and General Partner of Three Arch Bay Health Science Fund, a private investment fund focused on emerging biomedical companies, from 1993 to completion in 2011. He received an honorary doctorate of medical sciences from Oulu University, Oulu, Finland in 2009. He was a director of Kolltan Pharmaceuticals, a spin-out from Yale University, from 2009 to 2016. Mr. Neff is a named inventor on more than 100 of FibroGen’s patents and patent applications. |
Data sourced from SEC filings. Last updated: 2025-10-11